Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome
Currently, Class 1.1 innovative TCM drugs for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome) remain scarce.YRPG’s ZGZHR-061 Granules target this condition, fitting respiratory chronic disease needs.
The drug first filed for a clinical trial on March 13, 2026, and received approval on May 25, 2026.ZGZHR-061 Granules (Class 1.1 TCM) warm Yang, supplement Qi, unblock lung, and stop wheezing.It also relieves cough and phlegm for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome).Respiratory TCM drugs are a mainstream golden track in the pharma market, with huge volume and rigid long-term demand.
In 2025, total hospital sales of respiratory TCM drugs in China exceeded 50 billion RMB.In TCM innovation, YRPG has formed a tiered R&D structure.To date, YRPG has four Class 1.1 TCM drugs approved for clinical trials.They are ZGZHR-061 Granules, ZYY-742 Gel, Qingchang Wenzhong Tablets, and Qinqiao Yanshu Granules.These drugs cover multiple therapeutic areas, with continuous original R&D achievements from YRPG.
